上皮间质转化促乳腺癌机制及药物干预治疗研究进展

doi:10.16431/j.cnki.1671-7236.2021.01.013

摘要/Abstract

摘要： 乳腺癌是犬、猫等伴侣动物与人类常发疾病，作为人类及动物常患恶性肿瘤和主要致死肿瘤之一，其疾病负担仍呈逐步加重趋势，乳腺癌的预防及治疗形势愈加严峻。上皮间质转化（EMT）是乳腺癌发生发展中重要的生物学过程。EMT还可促进恶性肿瘤的侵袭、扩散及耐药，因此它在肿瘤的研究中日益受到关注，靶向于EMT是治疗乳腺癌的重要研究方向与热点。文章就EMT发生过程中细胞形态功能及标志物的变化、EMT分类及EMT与乳腺癌的关系分别展开论述，详细解析了EMT相关TGF-β/Smad、NF-κB及Wnt信号通路转导途径；随后对乳腺癌治疗药物研究进展，包括TGF-β/Smad通路抑制剂开发，相关药物、基因及细胞因子治疗前景、NF-κB通路与Wnt通路抑制剂的动物试验研究结果进行了详细论述；最后对乳腺癌的治疗发展与趋势进行了展望。深入认识信号通路调控乳腺癌EMT的生物学过程，明确其发生发展机制，寻找关键靶点及开发靶向药物，将为乳腺癌的精准治疗带来曙光。

关键词: 乳腺癌; 上皮间质转化; 靶向治疗; TGF-β/Smad; NF-κB; Wnt

Abstract: Breast cancer is a common disease in dogs,cats and other companion animals and humans.As a malignant tumor and the main cause of death of humans and animals,the disease burden of breast cancer is still gradually increasing,and the prevention and treatment situation of breast cancer is becoming more and more serious.Epithelial-mesenchymal transition (EMT) plays an important role in biological process in the development of breast cancer,which can also promote the invasion,metastasis and drug resistance of malignant tumors.Therefore,it is getting more and more attention in cancer research,and targeting EMT is an important research direction and hotspot in the treatment of breast cancer.In this paper,the changes of cell morphology and function and markers,the classification of EMT and the relationship between EMT and breast cancer were discussed respectively.The EMT-related TGF-β/Smad,NF-κB and Wnt signaling pathways were analyzed in detail.And then advances in the treatment of breast cancer,including the development of inhibitors of TGF-β/Smad pathway,the prospect of treatment with related drugs,genes and cytokines,and the experimental results of NF-κB pathway and Wnt pathway inhibitors,were discussed in detail.Finally,the development and trend of the treatment of breast cancer were prospected.Deeply understanding the biological process of breast cancer EMT regulated by signaling pathway,making clear its occurrence development mechanism,finding key targets and developing targeted drugs,will bring the dawn for the precise treatment of breast cancer.

Key words: breast cancer; epithelial-mesenchymal transition; targeted therapy; TGF-β/Smad; NF-κB; Wnt

中图分类号:

S853.74

林昌杰, 李婷, 唐鑫, 陈颖钰, 郭爱珍, 胡长敏. 上皮间质转化促乳腺癌机制及药物干预治疗研究进展[J]. 中国畜牧兽医, 2021, 48(1): 117-123.

LIN Changjie, LI Ting, TANG Xin, CHEN Yingyu, GUO Aizhen, HU Changmin. Advances in the Mechanism of Epithelial-mesenchymal Transition for Breast Cancer Promotion and Drug Intervention[J]. China Animal Husbandry and Veterinary Medicine, 2021, 48(1): 117-123.

参考文献

[1] RYBICKA A,KROL M.Identification and characterization of cancer stem cells in canine mammary tumors[J].Acta Veterinaria Scandinavica,2016,58(1):86.
[2] SHAFIEE R,JAVANBAKHT J,ATYBI N,et al.Retracted article:Diagnosis,classification and grading of canine mammary tumours as a model to study human breast cancer:An clinico-cytohistopathological study with environmental factors influencing public health and medicine[J].Cancer Cell International,2013,13(1):469.
[3] 师金,梁迪,李道娟,等.全球女性乳腺癌流行情况研究[J].中国肿瘤,2017,26(9):683-690. SHI J,LIANG D,LI D J,et al.Epidemiological status of global female breast cancer[J].China Cancer,2017,26(9):683-690.(in Chinese)
[4] 郭鱼波,王春晖,裴晓华.乳腺癌细胞上皮间质转化的分子机制及其防治的研究进展[J].中国肿瘤,2018,27(12):933-943. GUO Y B,WANG C H,PEI X Y.Research progress on molecular mechanism of epithelial mesenchymal transition in breast cancer cells and its prevention and treatment[J].China Cancer,2018,27(12):933-943.(in Chinese)
[5] ACLOQUE H,ADAMS M S,FISHWICK K,et al.Epithelial-mesenchymal transitions:The importance of changing cell state in development and disease[J].Journal of Clinicla Investigation,2009,119(6):1438-1449.
[6] GREENBURG G.Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells[J].Journal of Cell Biology,1982,95(1):333-339.
[7] 庞翠,张菊,刘文超.EMT研究进展[J].现代肿瘤医学,2016,24(15):2484-2487. PANG C,ZHANG J,LIU W C.The research progression of EMT[J].Modern Oncology,2016,24(15):2484-2487.(in Chinese)
[8] ZEISBERG M,NEILSON E G.Biomarkers for epithelial-mesenchymal transitions[J].Journal of Clinicl Investigation,2009,119(6):1429-1437.
[9] LAMOUILLE S,XU J,DERYNCK R.Molecular mechanisms of epithelial-mesenchymal transition[J].Nature Reviews Molecular Cell Biology,2014,15(3):178-196.
[10] FUXE J,KARLSSON M C.TGF-β-induced epithelial-mesenchymal transition:A link between cancer and inflammation[J].Seminars in Cancer Biology,2012,22(5-6):455-461.
[11] 周珏,李海莉,贾秀鹏,等.乳腺癌上皮间质转化的研究进展[J].现代实用医学,2019,31(12):1697-1699. ZHOU Y,LI H L,JIA X P,et al.The research progress of breast cancer epithelial-mesenchymal transition[J].Modern Practical Medicine,2019,31(12):1697-1699.(in Chinese)
[12] MOSES H L,ROBERTS A B,DERYNCK R.The discovery and early days of TGF-β:A historical perspective[J].Cold Spring Harbor Perspectives in Biology,2016,8(7):a021865.
[13] HAQUE S,MORRIS J C.Transforming growth factor-β:A therapeutic target for cancer[J].Human Vaccines Immunotherapeutics,2017,13(8):1741-1750.
[14] DERYNCK R,BUDI E H.Specificity,versatility,and control of TGF-β family signaling[J].Science Signaling,2019,12(570):eaav5183.
[15] HELDIN C H,MOUSTAKAS A.Signaling receptors for TGF-β family members[J].Cold Spring Harbor Perspectives in Biology,2016,8(8):a022053.
[16] HAO Y,BAKER D,TEN DIJKE P.TGF-β-mediated epithelial-mesenchymal transition and cancer metastasis[J].International Journal of Molecular Sciences,2019,20(11):2767.
[17] YAN X,LIAO H,CHENG M,et al.Smad7 protein interacts with receptor-regulated Smads (R-Smads) to inhibit transforming growth factor-β (TGF-β)/Smad signaling[J].The Journal of Bioligical Chemistry,2016,291(1):382-392.
[18] HATA A,CHEN Y G.TGF-β signaling from receptors to Smads[J].Cold Spring Harbor Perspectives Biology,2016,8(9):a022061.
[19] HUBER M A,AZOITEI N,BAUMANN B,et al.NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression[J].The Journal of Clinical Investigation,2004,114(4):569-581.
[20] PIRES B R,MENCALLHA A L,FERREIRA G M,et al.NF-κB is involved in the regulation of EMT genes in breast cancer cells[J].PLoS One,2017,12(1):e0169622.
[21] JAMSHIDI M,FAGERHOLM R,KHAN S,et al.SNP-SNP interaction analysis of NF-κB signaling pathway on breast cancer survival[J].Oncotarget,2015,6(35):37979-37994.
[22] ZHAN T,RINDTORFF N,BOUTROS M.Wnt signa-ling in cancer[J].Oncogene,2017,36(11):1461-1473.
[23] NAYAK L,BHATTCHARYYA N P,DE R K.Wnt signal transduction pathways:Modules,development and evolution[J].BMC Systems Biology,2016,10(Suppl 2):44.
[24] KRISHNAMURTHY N,KURZROCK R.Targeting the Wnt/β-catenin pathway in cancer:Update on effectors and inhibitors[J].Cancer Treatment Reviews,2018,62:50-60.
[25] WU Y,ZHOU B P.New insights of epithelial-mesenchymal transition in cancer metastasis[J].Acta Biochimica et Biophysica Sinica (Shanghai),2008,40(7):643-650.
[26] YIN P,WANG W,ZHANG Z,et al.Wnt signaling in human and mouse breast cancer:Focusing on Wnt ligands,receptors and antagonists[J].Cancer Science,2018,109(11):3368-3375.
[27] DARAKHSHAN S,GHANBARI A.Tranilast enhances the anti-tumor effects of tamoxifen on human breast cancer cells in vitro[J].Journal of Biomedical Science,2013,20:76.
[28] NIENHUIS H H,ARJAANS M,TIMMER-BOSSCHA H,et al.Human stromal cells are required for an anti-breast cancer effect of zoledronic acid[J].Oncotarget,2015,6(27):24436-24447.
[29] SOKOL J P,NEIL J R,SCHIEMANN B J,et al.The use of cystatin C to inhibit epithelial-mesenchymal transition and morphological transformation stimulated by transforming growth factor-β[J].Breast Cancer Research,2005,7(5):R844-853.
[30] TSAO S M,HSU H Y.Fucose-containing fraction of Ling-Zhi enhances lipid rafts-dependent ubiquitination of TGFβ receptor degradation and attenuates breast cancer tumorigenesis[J].Scientific Reports,2016,6:36563.
[31] SUN Y,ZHOU Q M,LU Y Y,et al.Resveratrol inhibits the migration and metastasis of MDA-MB-231 human breast cancer by reversing TGF-β1-induced epithelial-mesenchymal transition[J].Molecules,2019,24(6):1131.
[32] YU Y,LUO W,YANG Z J,et al.miR-190 suppresses breast cancer metastasis by regulation of TGF-β-induced epithelial-mesenchymal transition[J].Molecular Cancer,2018,17(1):70.
[33] YIN K,YIN W,WANG Y,et al.miR-206 suppresses epithelial mesenchymal transition by targeting TGF-β signaling in estrogen receptor positive breast cancer cells[J].Oncotarget,2016,7(17):24537-24548.
[34] NING J,ZHAO Y,YE Y,et al.Opposing roles and potential antagonistic mechanism between TGF-β and BMP pathways:Implications for cancer progression[J].EBioMedicine,2019,41:702-710.
[35] ZHU X,HUANG S,ZENG L,et al.HMOX-1 inhibits TGF-β-induced epithelial-mesenchymal transition in the MCF-7 breast cancer cell line[J].International Jouranl of Molecular Medicine,2017,40(2):411-417.
[36] HAMDOUN S,EFFERTH T.Ginkgolic acids inhibit migration in breast cancer cells by inhibition of NEMO sumoylation and NF-κB activity[J].Oncotarget,2017,8(21):35103-35115.
[37] HAN D,WU G,CHANG C,et al.Disulfiram inhibits TGF-β-induced epithelial-mesenchymal transition and stem-like features in breast cancer via ERK/NF-κB/Snail pathway[J].Oncotarget,2015,6(38):40907-40919.
[38] SPERLICH J,KERR R,TEUSCH N.The marine natural product pseudopterosin blocks cytokine release of triple-negative breast cancer and monocytic leukemia cells by inhibiting NF-κB signaling[J].Marine Drugs,2017,15(9):262.
[39] 魏业东.大黄素通过Wnt/β-catenin信号通路抑制三阴性乳腺癌转移及EMT效应的体外研究[D].上海:华东理工大学,2018. WEI Y D.Emodin inhibit triple negative breast cancer epithelial-mesenchymal transtition and cell metastasis via Wnt/β-catenin signaling in vitro[D].Shanghai:East China University of Science and Technology,2018.(in Chinese)
[40] MA X,YAN W,DAI Z,et al.Baicalein suppresses metastasis of breast cancer cells by inhibiting EMT via downregulation of SATB1 and Wnt/β-catenin pathway[J].Drug Design Development Therapy,2016,10:1419-1441.
[41] REN L,CHEN H,SONG J,et al.miR-454-3p-mediated Wnt/β-catenin signaling antagonists suppression promotes breast cancer metastasis[J].Theranostics,2019,9(2):449-465.